Vis enkel innførsel

dc.contributor.authorLiposits, Gabor
dc.contributor.authorSkuladottir, Halla
dc.contributor.authorRyg, Jesper
dc.contributor.authorWinther, Stine Brændegaard
dc.contributor.authorMöller, Sören
dc.contributor.authorHofsli, Eva
dc.contributor.authorShah, Carl-Henrik
dc.contributor.authorPoulsen, Laurids Østergaard
dc.contributor.authorBerglund, Åke
dc.contributor.authorQvortrup, Camilla
dc.contributor.authorOsterlund, Pia
dc.contributor.authorJohansen, Julia S.
dc.contributor.authorGlimelius, Bengt
dc.contributor.authorSorbye, Halfdan
dc.contributor.authorPfeiffer, Per
dc.description.abstractAppropriate patient selection for palliative chemotherapy is crucial in patients with metastatic colorectal cancer (mCRC). We investigated the prognostic value of C-reactive protein (CRP), derived neutrophil-to-lymphocyte ratio (dNLR), Interleukin (IL)-6, and YKL-40 on progression-free survival (PFS) and overall survival (OS) in the NORDIC9 cohort. The randomized NORDIC9-study included patients ≥70 years with mCRC not candidates for standard full-dose combination chemotherapy. Participants received either full-dose S1 (Teysuno) or a dose-reduced S1 plus oxaliplatin. Blood samples were collected at baseline and biomarkers were dichotomized according to standard cut-offs. Multivariable analyses adjusted for age, sex, ECOG performance status, and treatment allocation; furthermore, C-statistics were estimated. In total, 160 patients with a median age of 78 years (IQR: 76–81) were included between 2015 and 2017. All investigated biomarkers were significantly elevated in patients with either weight loss, ≥3 metastatic sites, or primary tumor in situ. In multivariable analyses, all markers showed significant association with OS; the highest HR was observed for CRP (HR = 3.40, 95%CI: 2.20–5.26, p < 0.001). Regarding PFS, statistically significant differences were found for CRP and IL-6, but not for dNLR and YKL-40. Applying C-statistics, CRP indicated a good prognostic model for OS (AUC = 0.72, 95%CI: 0.67–0.76). CRP is an easily available biomarker, which may support therapeutic decision-making in vulnerable older patients with mCRC.en_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.titleThe prognostic value of pre-treatment circulating biomarkers of systemic inflammation (CRP, dNLR, YKL-40, and IL-6) in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy—The Randomized NORDIC9-Studyen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.rights.holderCopyright 2022 The Author(s)en_US
dc.source.journalJournal of Clinical Medicineen_US
dc.identifier.citationJournal of Clinical Medicine. 2022, 11 (19), 5603.en_US

Tilhørende fil(er)


Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal